HDAC9 and neoplasm: HDAC-inhibitors have been implicated in the re-sensitization of tumor cells to cytotoxic drug treatment [12,13] and concomitant application of VPA with chemo- or targeted therapies has shown that VPA prevents tumor cells from becoming resistant [6,32].